🧾 What This Document Is

This is an 8-K filing, which companies use to announce major, unexpected events to investors. This specific filing contains a press release (Exhibit 99.1) announcing that Certara is selling a part of its business. The filing signals a significant strategic shift for the company.

🏢 What The Company Does

👉 In simple terms, Certara is a "drug development toolmaker." They create specialized computer software and models (called biosimulation) that pharmaceutical companies use to predict how a new drug will behave in the human body. This helps speed up and improve the chances of a drug's success, from initial discovery to regulatory approval.

🤝 The Deal

Certara has agreed to sell its Regulatory and Medical Writing business to a company called Veristat. This business unit helps prepare the complex documents and submissions required by regulatory agencies like the FDA.

💰 Price: Up to $135 million. 📅 Timing: The deal is expected to close in the second quarter of 2026. ⚠️ Condition: It must pass "customary closing conditions," which are standard legal and regulatory checks.

📊 Financial Breakdown of the Business Sold

The business being sold was a meaningful, but not dominant, part of Certara's operations. Here’s a snapshot of its 2025 performance:

• Revenue: $50 million
• Profitability (Adjusted EBITDA): $17 million
• People: The unit includes about 220 employees who will transfer to the new owner.

👉 Why it matters: This shows the unit was solidly profitable. Selling it provides Certara with a large cash infusion but means giving up a steady income stream.

🚀 Why They’re Doing This (The Strategy)

The CEO, Jon Resnick, is clear: this sale is about focus. Certara wants to double down on its core, high-tech strength—Model-Informed Drug Development (MIDD) and its new Clinical Intelligence platform. They believe integrating AI (Artificial Intelligence) into these modeling tools is the future. Selling the more traditional writing business sharpens this focus.

💸 What Happens With The Money?

Certara plans to use the $135 million in proceeds to "drive long-term value." While not specified, this typically means reinvesting in the core business through R&D, new product development, or strategic acquisitions that align with their MIDD and AI goals.

🔮 What's Next For Certara

With a smaller, more focused business, Certara will need to update its financial outlook. The company stated it will provide new 2026 guidance after the transaction officially closes. Investors will watch closely to see how the company projects its growth without the sold business unit.

🧠 The Analogy

Think of Certara as a high-end restaurant that was famous for both its innovative molecular gastronomy (the MIDD software) and its classic, traditional catering service (the writing business). By selling the catering arm, the restaurant can free up kitchen space, chefs, and capital to invent even more groundbreaking dishes, fully committing to its cutting-edge culinary identity.

🧩 Final Takeaway

Certara is selling a profitable but non-core business for a significant sum to sharpen its focus on its high-tech, AI-driven drug development simulation software. The move is a clear strategic bet on becoming a leader in the most advanced, computational corner of the pharmaceutical industry.